AstraZeneca PLC (AZN )
Currency in USD Disclaimer
Subscribe Now for Delta3 AI Alerts
Don’t miss out on top stock picks and market insights. Subscribe to Delta3 AI Alerts for real-time updates and expert analysis straight to your inbox. Stay informed and maximize your investment potential.
Key Stats
Key stats represent essential financial metrics and indicators used to evaluate a company's performance and potential investment opportunities.
- Symbol AZN
- Company AstraZeneca PLC
- Price $203.49
- Changes Percentage 1.37
- Change 2.76
- Day Low $199.23
- Day High $204.34
- Year High $212.71
- Year Low $122.48
- Market Cap $157,733,597,556
- Price Avg 50 EMA (D) $194.72
- Price Avg 200 EMA (D) $171.71
- Exchange NYSE
- Volume 1,919,373
- Average Volume 3,031,729
- Open $199.67
- Previous Close $200.73
- EPS 6.53
- PE 31.16
- Earnings Announcement 2026-04-29 20:00:00
- Shares Outstanding $775,141,764
Company brief: ASTRAZENECA PLC (AZN )
- Healthcare
- Drug Manufacturers - General
- Mr. Pascal Soriot D.V.M., M.B.A.
- https://www.astrazeneca.com
- GB
- N/A
- 05-12-1993
- US0463531089
AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacturing, and commercialization of prescription medicines. Its marketed products include Calquence, Enhertu, Faslodex, Imfinzi, Iressa, Koselugo, Lumoxiti, Lynparza, Orpathys, Tagrisso, and Zoladex for oncology; Brilinta/Brilique, Bydureon/Byetta, BCise, Byetta, Crestor, Evrenzo, Farxiga/Forxiga, Komboglyze/Kombiglyze XR, Lokelma, Onglyza, Qtern, and Xigduo/Xigduo XR for cardiovascular, renal, and metabolism diseases; Bevespi Aerosphere, Breztri Aerosphere, Daliresp/Daxas, Duaklir Genuair, Fasenra, Pulmicort, Saphnelo, Symbicort, and Tudorza/Eklira/Bretaris for respiratory and immunology; and Andexxa/Ondexxya, Kanuma, Soliris, Strensiq, and Ultomiris for rare diseases. The company's marketed products also comprise Synagis for respiratory syncytial virus; Fluenz Tetra/FluMist Quadrivalent for Influenza; Seroquel IR/Seroquel XR for schizophrenia bipolar disease; Nexium, and Losec/Prilosec for gastroenterology; and Vaxzevria and Evusheld for covid-19. The company serves primary care and specialty care physicians through distributors and local representative offices in the United Kingdom, rest of Europe, the Americas, Asia, Africa, and Australasia. It has a collaboration agreement with Regeneron Pharmaceuticals, Inc. to research, develop, and commercialize small molecule medicines for obesity; Neurimmune AG to develop and commercialize NI006; Ionis Pharmaceuticals, Inc. to develop eplontersen, a liver-targeted antisense therapy in Phase III development for the treatment of transthyretin amyloidosis; Proteros Biostructures GmbH to jointly discover novel small molecules for the treatment of hematological cancers; Sierra Oncology, Inc. to develop and commercialize AZD5153. The company was formerly known as Zeneca Group PLC and changed its name to AstraZeneca PLC in April 1999. AstraZeneca PLC was incorporated in 1992 and is headquartered in Cambridge, the United Kingdom.
AZN Corporation News
Astrazeneca (AZN) Rises Higher Than Market: Key Facts
zacks.com -- Astrazeneca (AZN) concluded the recent trading session at $203.49, signifying a +1.37% move from its prior day's close....
Trump Administration Unveils Up to 100% Tariff on Branded Drugs
wsj.com -- Drugmakers or countries that strike pricing deals or make manufacturing investment commitments in the U.S. can secure much lower levies, or none at all....
AstraZeneca's liver cancer therapy combo slows disease progression in late-stage trial
reuters.com -- AstraZeneca said on Thursday that a combination treatment with its cancer drug Imfinzi showed significant improvement in how long patients with a common liver cancer lived before their disease wors...
AZN Posts Data From Hypophosphatasia Program on Efzimfotase Alfa
zacks.com -- AstraZeneca reports phase III data showing efzimfotase alfa improves bone health in children with HPP, with mixed adult results and an overall favorable safety profile....
US bank sees AstraZeneca HPP drug data as supportive of $2.6bn forecast with upside to $4.4bn despite mixed trial results
proactiveinvestors.co.uk -- AstraZeneca PLC (LSE:AZN, NASDAQ:AZN) has reported mixed phase three trial data for efzimfotase alfa, its treatment for hypophosphatasia, a rare genetic disease that impairs the body's ability to mine...
AstraZeneca Confident Rare-Disease Drug Can Hit Target After Mixed Study Results
wsj.com -- The company said the results support the drug's potential to transform the treatment of hypophosphatasia and it plans to submit data to regulators as soon as possible....
Tozorakimab trial success hands AstraZeneca a crucial edge in the race to crack COPD's hardest-to-treat patients
proactiveinvestors.co.uk -- Friday's positive trial results for tozorakimab mark a significant inflexion point for AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), arriving at a moment when the market had all but written off the drug's pr...
Guggenheim Raises AstraZeneca Price Target Ahead of Q1 Earnings
247wallst.com -- AstraZeneca PLC (NASDAQ:AZN) has delivered a solid trailing 12 months, with shares up 31.43% over the past year....
AZN Stock Gains as COPD Drug Clears Two Late-Stage Studies
zacks.com -- AstraZeneca jumps as tozorakimab hits primary goals in two phase III COPD trials, cuts exacerbations and shows promise in a disease with limited options....